BioAlliance Pharma extends and strengthens the protection of AMEP® with the grant of two patents in the US

Regulatory News:

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces two key achievements in the development of its biotherapy AMEPwith the decision of granting two patents by the USPTO (United States Patent and Trademark Office).

AMEP is a protein targeting specific receptors expressed on melanoma cells and involved in both tumor growth and angiogenesis (inhibition of tumor vascularization necessary for its growth). As the protein cannot be directly administered, the Company has developed a technology aiming at administering the specific gene (the AMEPbiotherapy) which, once inside the cell, will enable synthesis of the active AMEP protein.

After Asia and Europe, BioAlliance Pharma has obtained the US patent protecting the metastatic melanoma treatment by the AMEP biotherapy. This patent provides a protection until 2022. Moreover, the USPTO has recently given its allowance to deliver another patent on this same product to BioAlliance Pharma, covering the specific method of administration of the gene coding for AMEP protein until 2026.

declares Aude Michel, Vice President Licensing and Legal Affairs, and European Patent Attorney of BioAlliance Pharma.

BioAlliance Pharma is pursuing the development of AMEP with a second European Phase I/II trial via intramuscular administration. It aims at evaluating the safety and efficacy profile via systemic route in patients with metastatic melanoma.

added Judith Greciet, CEO of BioAlliance Pharma.

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Loramyc/Oravig (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir/Sitavig (Acyclovir Lauriad) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad (chronic cancer pain): Positive preliminary Phase I results

Livatag (Doxorubicin Transdrug™) (primary liver cancer): Phase III on going

Validive (Clonidine Lauriad) (mucositis): Phase II on going

AMEP (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.